|
| |
Novozymes Biopharma to Showcase Animal-Free Cell
Culture Portfolio at ESACT 2009
Nottingham, UK (5 June 2009). Novozymes Biopharma, part of Novozymes, world
leader in bioinnovation, will be showcasing its animal-free cell culture
portfolio on booth #40 at the 21st Meeting of the European Society for Animal
Cell Technology (ESACT), 7-10 June 2009, CityWest Hotel, Dublin, Ireland.
As part of its cell culture portfolio, Novozymes Biopharma will be showcasing
its’ products within the CellPrime™ brand. This includes two newly launched
products, CellPrime rTransferrin AF, and CellPrime rAlbumin AF-G. Both products
are manufactured by Novozymes Biopharma and sold exclusively through Millipore
Corporation as part of the CellPrime alliance.
CellPrimeTM rTransferrin AF is the first animal-free alternative to
serum-derived human or bovine transferrin for industrial cell culture and
upstream biopharmaceutical applications. It is designed to reduce risk and ease
regulatory concerns as it improves the consistency of batch quality and
productivity of customers’ industrial cell culture processes. Manufactured in
FDA-inspected facilities to cGMP standards, CellPrime™ rTransferrin AF is
suitable for both research and commercial scale mammalian cell culture.
CellPrimeTM rAlbumin AF-G is an animal free, recombinant human albumin developed
specifically for large scale industrial cell culture. It offers multiple
benefits including the maintenance of osmotic balance and transport, the
distribution of fatty acids and amino acids, as well as improving consistency of
customers’ industrial cell culture processes.
Novozymes Biopharma will also exhibit LONG®R3 IGF-I, an analogue of human
insulin-like growth factor I (IGF-I) specifically engineered by Novozymes
Biopharma for use in industrial cell culture. LONG®R3 IGF-I provides improved
performance and a consistent, compliant and animal-free alternative to
recombinant insulin. This product is manufactured by Novozymes Biopharma and
sold exclusively through SAFC Biosciences.
Novozymes Biopharma will present a number of technical discussions including:-
• A presentation entitled “Regulation of IGF-I and transferrin receptor numbers
at the cell surface may drive growth and productivity of hybridoma cells”
authored by Andrew J Sakko1, Kenneth C Bertram, Sally Grosvenor, Danny Voorhamme,
Anthony Simula and Geoffrey L Francis, Novozymes Biopharma AU Ltd. This will be
held on Tuesday June 9th at 12pm in the main plenary room, Convention 1 and 2.
• A poster entitled “Recombinant Albumin as an animal-free supplement for cell
culture applications” authored by Collette Sheahan, Novozymes Biopharma AU Ltd.
This will be held on Tuesday 9th June at 14.40hrs – 17.40hrs held at the
Refreshments and Poster Session 1 (Poster # P240)
• A poster entitled “Utilising scale-up model systems to optimise upstream
process development” authored by Sally Grosvenor, Larissa Chirkova and Kenneth
Bertram, Novozymes Biopharma AU Ltd. This will be held on Wednesday 10th June at
10.30hrs – 13.00hrs held at the Refreshments and Poster Session 2 (Poster # P97)
To learn more about Novozymes Biopharma’s portfolio of cell culture products,
please visit booth #40 at ESACT 2009. Alternatively please email Sally Vernon,
Marketing Communications Manager, at
SYKE@novozymes.com or visit
www.biopharma.novozymes.com
About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers
across a broad array of industries we create tomorrow’s industrial biosolutions,
improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes’ bioinnovations improve
industrial performance and safeguard the world’s resources by offering superior
and sustainable solutions for tomorrow’s ever-changing marketplace.
Novozymes’ natural solutions enhance and promote everything from removing trans
fats in cooking, to advancing biofuels to power the world tomorrow. Our
never-ending exploration of nature’s potential is evidenced by over 6,000
patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world
are committed to shaping business today and our world tomorrow.
Contacts:
Novozymes Biopharma:
Sally Vernon, Marketing Communications Manager
SYKE@novozymes.com
Corporate Contacts:
Press and media:
Johan Melchior
Tel. (direct): +45 4446 0690
Tel. (mobile): +45 3077 0690
René Tronborg
Tel. (direct): +45 4446 2274
Tel. (mobile): +45 3077 2274
Paige Donnelly (USA)
Tel. (direct): +1 919 494 3209
Tel. (mobile): +1 919 218 4501
Investor relations:
Camilla Kinch Jensen
Tel. (direct): +45 4446 0852
Tel. (mobile): +45 3077 0852
Tobias Bjørklund (USA)
Tel. (direct): +1 919 494 3483
Tel. (mobile): +1 919 649 2565
| |
|
